NEW YORK (GenomeWeb) – SISCAPA Assay Technologies said this week that it has closed a Series A financing round.
The company did not disclose the amount raised or the investors involved, but said that it planned to use the funds to develop diagnostic products for wellness and chronic disease monitoring.
Specifically, SAT aims to validate the use of SISCAPA panels for analysis of dried blood spot samples and longitudinal testing.
"Our goal is to provide a better patient experience for the sampling and longitudinal testing of key protein biomarkers," SAT President and CEO Gustavo Salem said in a statement. "Changing the paradigm to more frequent testing, at a lower cost, for the benefit of assessing changes in one’s personal baseline is the new model for improved health management.”
SAT was launched in 2011 by Leigh Anderson to commercialize the SISCAPA immunoaffinity-based mass spec assay he developed.
Short for stable isotope standards and capture by anti-peptide antibodies — SISCAPA combines antibody-based peptide enrichment with mass spectrometry, increasing the sensitivity of mass spec instruments, which by themselves are often not sensitive enough to detect low-abundance proteins in complex samples.